BioConsortia, a California-based company developing biofertilizer, pest management, and biostimulant products, has announced its largest proprietary field trial program to date, with hundreds of tests planned or underway for the 2023 field season. These field trials are the final stage of developing the company’s new products for nitrogen fixation, nematode control, disease control, and plant biostimulation.

BioConsortia plans to conduct field trials in 2023 in Asia, Latin America, Europe, and North America, with potential commercial collaborators and existing partners such as The Mosaic Company to increase its understanding of BioConsortia's microbial products. 

BioConsortia has also closed an internal financing round led by existing investor Otter Capital, excited by ongoing product development progress and expansion into new territories, including Brazil and Europe. BioConsortia plans to use the new capital to fuel international growth, expand its ecosystem of commercial partners, and advance its pipeline of transformational products for agriculture.

Analyst QuickTake: BioConsortia previously advanced two new nematicides into the development pipeline, which were validated through field trials in December 2022. Additionally, the company is actively partnering with major firms in the seed, seed treatment, and crop protection segments to take its products worldwide for various agriculture applications.